Is there a pharmacological basis for therapy with rapid opioid detoxification?
Spanagel
R
R
Department of Psychopharmacology, Max Planck Institute of Psychiatry, Munich, Germany.
D000768:Anesthesia, General; D000818:Animals; D016292:Procedural Sedation; D017362:Cyclic AMP Response Element-Binding Protein / Q000037:antagonists & inhibitors; D006556:Heroin Dependence / Q000534:rehabilitation*; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D009270:Naloxone / Q000008:administration & dosage / Q000009:adverse effects; D009271:Naltrexone / Q000008:administration & dosage / Q000009:adverse effects; D009292:Narcotic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D017450:Receptors, Opioid, mu / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control*; D016896:Treatment Outcome
D017362:Cyclic AMP Response Element-Binding Protein; D009292:Narcotic Antagonists; D017450:Receptors, Opioid, mu; D009270:Naloxone; D009271:Naltrexone